The peripheral blood mononuclear cell microRNA signature of coronary artery disease

Hoekstra, Menno; Lans, Christian A.C. Van der; Halvorsen, Bente; Gullestad, Lars; Kuiper, Johan; Aukrust, Pål; Berkel, Theo J.C. Van; Biessen, Erik A. L.

doi:10.1016/j.bbrc.2010.03.075

Cited by 200 publications

(163 citation statements)

References 31 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…A cluster of the three miRNAs miR-134, miR-198, and miR-370 was identified overexpressed in peripheral blood mononuclear cells (PBMC) of 25 UAP patients compared with 25 SAP patients. Importantly, this miRNA signature was able to differentiate UAP from SAP in this patient collective [89]. Similar results were reported when a set of microparticle-derived pro-inflammatory miRNAs from plasma of 10 patients was observed to discriminate between SAP and UAP [90].…”

Section: Mirnas In the Diagnosis Of Unstable And Stable Angina Pectorsupporting

confidence: 87%

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

104

View full text Add to dashboard Cite

microRNAs (miRNAs) are well-known, powerful regulators of gene expression, and their potential to serve as circulating biomarkers is widely accepted. In cardiovascular disease (CVD), numerous studies have suggested miRNAs as strong circulating biomarkers with high diagnostic as well as prognostic power. In coronary artery disease (CAD) and heart failure (HF), miRNAs have been suggested as reliable biomarkers matching up to established protein-based such as cardiac troponins (cT) or natriuretic peptides. Also, in other CVD entities, miRNAs were identified as surprisingly specific biomarkers -with great potential for clinical applicability, especially in those entities that lack specific protein-based biomarkers such as atrial fibrillation (AF) and acute pulmonary embolism (APE). In this regard, miRNA signatures, comprising a set of miRNAs, yield high sensitivity and specificity. Attempts to utilize miRNAs as therapeutic agents have led to promising results. In this article, we review the clinical applicability of circulating miRNAs in CVD. We are giving an overview of miRNAs as biomarkers in numerous CVD entities to depict the variety of their potential clinical deployment. We illustrate the function of miRNAs by means of single miRNA examples in CVD.

show abstract

Section: Mirnas In the Diagnosis Of Unstable And Stable Angina Pectorsupporting

confidence: 87%

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

104

View full text Add to dashboard Cite

show abstract

“…Using miRNA arrays, circulating miRNA signatures were studied in plasma of 8 stable CAD patients versus 8 healthy volunteers and this resulted in the identification of 46 downregulated miRNAs and 20 significantly upregulated miRNAs in plasma of these patients. In another study, Hoekstra et al, 40 have demonstrated that in stable and unstable CAD patients, 157 miRNAs were measured from PBMCs and differential expression was found. Most of the identified and validated downregulated miRNAs (miR-126, miR-92a, miR-155 and miR-17) were abundantly expressed in the endothelial cells of vessel wall.…”

Section: Coronary Heart Diseasementioning

confidence: 98%

“…Furthermore, patients with unstable AP could be discerned from stable patients, due to increased levels of miR-134, miR-198 and miR-370, further exemplifying the use of specific miRNA signatures in the identification of patients at risk for CAD. 40 Ren et al, 41 have identified a distinct plasma miRNA expression pattern in vulnerable CAD patients. They found upregulation miR-106b/25 cluster, miR-17/ 92a cluster, miR-21/590-5p family, miR-126 and miR-451, in unstable CAD patients compared to patients with non-cardiac chest pain.…”

Section: Coronary Heart Diseasementioning

confidence: 99%

“…40 Freedman et al 46 have demonstrated that PBMCs and platelets expressed 19 miRNAs. However, it is not known why the non-nucleated cells like platelets would express miRNAs?…”

Section: Coronary Heart Diseasementioning

confidence: 99%

“…However, it is not known why the non-nucleated cells like platelets would express miRNAs? Hoekstra et al 40 also studied the miRNA signature in the PBMCs of CAD patients. In a study group of 20 control subjects, 25 subjects with stable CAD, and 25 subjects with unstable CAD, real-time PCR analysis of 157 different miRNAs revealed that in PBMCs of both patient groups, circulating miR-135a was increased 5-fold, whereas miR-147 was decreased 4-fold compared with healthy control subjects.…”

Section: Coronary Heart Diseasementioning

confidence: 99%

See 2 more Smart Citations

Regulatory Noncoding RNAs in Cardiovascular Disease: Shedding Light on ‘Dark Matter’

Kudumula¹

2015

jcvd

View full text Add to dashboard Cite

301Abstract Cardiovascular disease (CVD) remains a major cause of morbidity and mortality worldwide accounting for more deaths than any other cause. CVD is regulated by stage-specific gene expression which, in turn, is controlled by myriads of regulatory noncoding RNAs (ncRNAs or miRNAs). Rapid advancement in genome mining technologies has identified different miRNAs in various tissues and body fluids. It is now well accepted that miRNAs represent critical regulators of cardiovascular function. The present review focuses primarily on recent updates on the basic miRNA biology; CVD-miRNA based research progress and functional significance of circulating noncoding RNAs. We also discuss their potential use as biomarkers and/or therapeutic targets in CVD.

show abstract